CA2269034A1 - Use of fasl or fasl transfected cd4+/fasl-/th1-cell lines for the treatment of th1/th2 diseases - Google Patents
Use of fasl or fasl transfected cd4+/fasl-/th1-cell lines for the treatment of th1/th2 diseases Download PDFInfo
- Publication number
- CA2269034A1 CA2269034A1 CA002269034A CA2269034A CA2269034A1 CA 2269034 A1 CA2269034 A1 CA 2269034A1 CA 002269034 A CA002269034 A CA 002269034A CA 2269034 A CA2269034 A CA 2269034A CA 2269034 A1 CA2269034 A1 CA 2269034A1
- Authority
- CA
- Canada
- Prior art keywords
- fasl
- application
- treatment
- fast
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 30
- 101150089023 FASLG gene Proteins 0.000 title description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 claims abstract description 27
- 102000015212 Fas Ligand Protein Human genes 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 102000004127 Cytokines Human genes 0.000 claims abstract description 9
- 108090000695 Cytokines Proteins 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims description 39
- 244000052769 pathogen Species 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 229940079322 interferon Drugs 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 206010024641 Listeriosis Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000009278 visceral effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 230000003389 potentiating effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 230000006882 induction of apoptosis Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 80
- 241000699670 Mus sp. Species 0.000 description 36
- 210000002540 macrophage Anatomy 0.000 description 35
- 230000003902 lesion Effects 0.000 description 29
- 108010052621 fas Receptor Proteins 0.000 description 26
- 102000018823 fas Receptor Human genes 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 241000222732 Leishmania major Species 0.000 description 19
- 244000045947 parasite Species 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000011740 C57BL/6 mouse Methods 0.000 description 17
- 241000222722 Leishmania <genus> Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- 208000004554 Leishmaniasis Diseases 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000029662 T-helper 1 type immune response Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000191796 Calyptosphaeria tropica Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000222740 Leishmania braziliensis Species 0.000 description 2
- 241000178949 Leishmania chagasi Species 0.000 description 2
- 241000222727 Leishmania donovani Species 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 244000020186 Nymphaea lutea Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150009153 COG6 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 101100272680 Paracentrotus lividus BP10 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000222714 Trypanosomatidae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are the use of FasL as active pharmacological component in the treatment of TH1/TH2 diseases, compositions containing FasL and one or more cytokines, specially interferon-.gamma., the use of a composition according to claims 11 and 12 for the treatment of TH1/TH2 diseases, the use of autologous Cd4+/FasL-/TH1 cell lines of the patient, transfected with the FasL gene sequence or with physiologically active fragments of the FasL gene sequence for the treatment of TH1/TH2 diseases.
Description
'.
Application of Fast or CD4+/FasL-/TI31 cell lines transfected with Fast for the treatment of THl/TH2 diseases. Method for the preparation of CD4+/FasL+/THl cell lines and material composition of Fast and one or several cytokines as well as their application for the treatment of TH1/TH2 diseases.
The invention concerns the application of Fast for the treatment of TH1/TH2 diseases, especially leishmaniosis, AmS, listeriosis, a method for the preparation of CD4+/FasL+/THl cell lines from CD4+/Fasl~/TH1 cell lines, their application for the treatment of TH1/TH2 diseases, a material composition containing Fast and one or several cytokines, as well as their 2 0 application as drugs, especially for the treatment of TH1/TH2 diseases.
TH1/TH2 diseases include a spectrum of immunologically caused disorders, which are based on a shift of the immune response or of an inadequate immune response after infection by pathogens, for example, viruses, bacteria 2 5 or protozoa.
The immune system of animals or humans responds to infection with pathogens by a cellular and/or a humoral immune reaction, depending on specific characteristics of the pathogen. While the cellular immune response is used mostly against intracellular parasites, the humoral immune response is characterized by the production of antibodies, which neutralize the pathogens extracellularly. B-lymphocytes participate especially in the humoral immune response, while the class T-lymphocytes participate both in cellular as well as humoral immune response. Therefore, one distinguishes between two different subclasses of T-lymphocytes, namely CDS+ cells, which carry a surface molecule designated with CDB, and analogously a subclass (CD4+ cells), which have the CD4 marker. These T-cells which carry CD4 are also called T-helper cells (TIT). _ T-helper cells are again subdivided into two subclasses, into the so-called TH1 cells and TH2 cells. Both cell classes occupy central positions in the combatting of intracellular or extracellular pathogens. The inflammatory TH1 cells serve as immune response against intracellular pathogens, such as Leishmania, viruses or intracellular parasitary bacteria, such as Listeria. On the other hand, Thi2 cells cause activation of B-lymphocytes, which - as mentioned above - control the humoral immunity against extracellular pathogens.
2 0 For adequate immune response to infection, it is of decisive importance that the TH1- or TH2-guided immune response predominates, depending on the type of pathogen. If, in an infection with intracellular parasitary pathogens, the THZ-guided immune response dominates, that is, if sufficient Tlil-guided immune response is lacking or is deficient, then in the sense of this invention, we are dealing with a TH1/TH2 disease.
It is known from the literature that TH1 cells exert a cytolytic action through a pathway controlled by Fas ligands (Fast) or Fas receptor (FasR) (Ashany, D., Song, X., Lacy, E., Nikoliczugic, J., Friedman, S. M. and Elkon, K.
Application of Fast or CD4+/FasL-/TI31 cell lines transfected with Fast for the treatment of THl/TH2 diseases. Method for the preparation of CD4+/FasL+/THl cell lines and material composition of Fast and one or several cytokines as well as their application for the treatment of TH1/TH2 diseases.
The invention concerns the application of Fast for the treatment of TH1/TH2 diseases, especially leishmaniosis, AmS, listeriosis, a method for the preparation of CD4+/FasL+/THl cell lines from CD4+/Fasl~/TH1 cell lines, their application for the treatment of TH1/TH2 diseases, a material composition containing Fast and one or several cytokines, as well as their 2 0 application as drugs, especially for the treatment of TH1/TH2 diseases.
TH1/TH2 diseases include a spectrum of immunologically caused disorders, which are based on a shift of the immune response or of an inadequate immune response after infection by pathogens, for example, viruses, bacteria 2 5 or protozoa.
The immune system of animals or humans responds to infection with pathogens by a cellular and/or a humoral immune reaction, depending on specific characteristics of the pathogen. While the cellular immune response is used mostly against intracellular parasites, the humoral immune response is characterized by the production of antibodies, which neutralize the pathogens extracellularly. B-lymphocytes participate especially in the humoral immune response, while the class T-lymphocytes participate both in cellular as well as humoral immune response. Therefore, one distinguishes between two different subclasses of T-lymphocytes, namely CDS+ cells, which carry a surface molecule designated with CDB, and analogously a subclass (CD4+ cells), which have the CD4 marker. These T-cells which carry CD4 are also called T-helper cells (TIT). _ T-helper cells are again subdivided into two subclasses, into the so-called TH1 cells and TH2 cells. Both cell classes occupy central positions in the combatting of intracellular or extracellular pathogens. The inflammatory TH1 cells serve as immune response against intracellular pathogens, such as Leishmania, viruses or intracellular parasitary bacteria, such as Listeria. On the other hand, Thi2 cells cause activation of B-lymphocytes, which - as mentioned above - control the humoral immunity against extracellular pathogens.
2 0 For adequate immune response to infection, it is of decisive importance that the TH1- or TH2-guided immune response predominates, depending on the type of pathogen. If, in an infection with intracellular parasitary pathogens, the THZ-guided immune response dominates, that is, if sufficient Tlil-guided immune response is lacking or is deficient, then in the sense of this invention, we are dealing with a TH1/TH2 disease.
It is known from the literature that TH1 cells exert a cytolytic action through a pathway controlled by Fas ligands (Fast) or Fas receptor (FasR) (Ashany, D., Song, X., Lacy, E., Nikoliczugic, J., Friedman, S. M. and Elkon, K.
B.; Proc. Natl. Acad. Sci. USA 92, 11225-11229, 1995; Ju, S. T., Cui, H., Panka, D. J., Ettinger, R., and Marshak, R. A.: Proc. Natl. Acad. Sci.
USA 91, 4185-4189, 1994; Richardson, B. C., Buckmaster, T., Keren, D.
F. and Johnson, K. J.; Eur. J. Immunol. 23, 1450-1455, 1993). Moreover, it was described that cloned TH1 cells have a high expression rate of Fast, in contrast to cloned TH2 cells (Hahn, S., Stalder, T., Wernli, M., Burgin, D., Tschopp, J., Nagata, S., and Erb, P., Eur. J. Immunol. 25, 2679-2685, 1995; Ramsdell, F., Seaman, M. S., Miller, R. E., Picha, K. S., Kennedy, M. K. and Lynch, D., Int. Immunol. 6, 1545-1553, 1994; Suda, T., Okazaki, T. , Naito, Y. , Yokota, T. , Arai, N. , Ozaki, S. , Nakao, K. and Nagata, S. J. Immunol. 154, 3806-3813, 1995). When Fast is bonded to its receptor, FasR, a cascade of signals is triggered, which finally lead to cell death (apoptosis) (Nagata, S. and Golstein; P., Science 267, 1449-1456, 1995). With the triggering of the death of an infected cell, the multiplication cycle of the intracellular pathogen is also interrupted.
Furthermore, it is described that, as a result of the activity of the inflammatory TH1 cells, to give off Fast in a direct manner, various target cells of greatly varied tissues, including macrophages, can be killed in vitro 2 0 as a result of the expression of FasR (Ashany, D. , Song, X. , Lacy, E. , Nikoliczugic, J., Friedman, S. M. and Elkon, K. B.; Proc. Natl. Acad. Sci.
USA 92, 11225-11229, 1995, Ju, S. T., Cui, H.,~Panka, D. J., Ettinger, R., and Marshak, R. A.; Proc. Natl. Acad. Sci. USA 91, 4185-4189, 1994;
Richardson, B. C., Buckmaster, T., Keren, D. F. and Johnson, K. J.; Eur.
J. Immunol. 23, 1450-1455, 1993).
Leishmania is a characteristic example of the class of pathogens which cause intracellular infection.
USA 91, 4185-4189, 1994; Richardson, B. C., Buckmaster, T., Keren, D.
F. and Johnson, K. J.; Eur. J. Immunol. 23, 1450-1455, 1993). Moreover, it was described that cloned TH1 cells have a high expression rate of Fast, in contrast to cloned TH2 cells (Hahn, S., Stalder, T., Wernli, M., Burgin, D., Tschopp, J., Nagata, S., and Erb, P., Eur. J. Immunol. 25, 2679-2685, 1995; Ramsdell, F., Seaman, M. S., Miller, R. E., Picha, K. S., Kennedy, M. K. and Lynch, D., Int. Immunol. 6, 1545-1553, 1994; Suda, T., Okazaki, T. , Naito, Y. , Yokota, T. , Arai, N. , Ozaki, S. , Nakao, K. and Nagata, S. J. Immunol. 154, 3806-3813, 1995). When Fast is bonded to its receptor, FasR, a cascade of signals is triggered, which finally lead to cell death (apoptosis) (Nagata, S. and Golstein; P., Science 267, 1449-1456, 1995). With the triggering of the death of an infected cell, the multiplication cycle of the intracellular pathogen is also interrupted.
Furthermore, it is described that, as a result of the activity of the inflammatory TH1 cells, to give off Fast in a direct manner, various target cells of greatly varied tissues, including macrophages, can be killed in vitro 2 0 as a result of the expression of FasR (Ashany, D. , Song, X. , Lacy, E. , Nikoliczugic, J., Friedman, S. M. and Elkon, K. B.; Proc. Natl. Acad. Sci.
USA 92, 11225-11229, 1995, Ju, S. T., Cui, H.,~Panka, D. J., Ettinger, R., and Marshak, R. A.; Proc. Natl. Acad. Sci. USA 91, 4185-4189, 1994;
Richardson, B. C., Buckmaster, T., Keren, D. F. and Johnson, K. J.; Eur.
J. Immunol. 23, 1450-1455, 1993).
Leishmania is a characteristic example of the class of pathogens which cause intracellular infection.
Leishmania (L.) belongs to the family of Trypanosomatidae and causes visceral, cutaneous or mucosal leishmanioses through its various human-pathogenic species (L. donovani, L. infantum, L. chagasi, L. tropica, L.
major, L. braziliensis, L. mexicana). L. attacks exclusively the endolysosomal compartments of macrophages. The immune response is based only on CD4+ cells.
Heinzel et al. (Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R.
L. and Locksley, R. M.; J. Exp. Medecine 169, 59-72, 1989) and Kemp et al. (Kemp, M., Theander, T. G. and Kharazmi, A.; Immunology today 17, 13-16, 1996) have infected two different resistant bred strains (C57BL/6 or C3H/Hel~ with L. major using the experimental mouse model for leishmanioses that reflects the human-immunological relationships. It is known from the document cited above, that especially the TH1 subclass of the CD4+ cells is responsible for the resistance of both bred strains.
Moreover, it is known from the papers of Heinzel, F. P., Sadick, M. D., Holaday, B. J. , Coffman, R. L. , and Locksley, R. M. , Journal of Experimental Medicine 169, 59-72, 1989 and Sadick, M. D., Locksley, R.
M., Tubbs, C. and Ruff, H. V.; J. Immunol. 136, 655-661, 1986; that the genetically nonresistant mouse strains such as Balb/c, react immunologically to the Leishmania infection with activation of the TH2 cells, but these cannot combat the Leishmania infection as signallers for antibody production.
Kemp, M. , Theander, T. G. and Kharazmi, A. (Immunology today 17, 13-2 5 16, 1996) showed that in human infection with L. - corresponding to the mouse model - an activation pattern of TH1 or TH2 cells exists which correspond to resistance or nonresistance.
._ ____.__ .. _._._ _ . ._ . .. . _. .._.._ _ . .. _.__. .. . . __ _ _ . ._ .
_ .. _ o .___ .. __.. _ __ ._ .. ___ . _ From the publication of Mosmann & Coffman (Mosmann, T. R. and Coffman, R. L., Annu. Rev. Immunol. 7, 145, 1989) it is known that a characteristic pattern of cytokines accompanies the activation of TH1- or TH2 cells. Thus, TH1 cells produce especially y-interferon (IFN-y), while 5 TH2 cells produce interleukin-4 (ZL-4).
It was shown both for the mouse model (Kemp, M. , Theander, T. G. and Kharazmi, A.; Immunology today 17, 13-16, 1996) as well as by clinical experiments (Gaafar, A. , Kharazmi, A. , Ismail, A. , Kemp, M. , Hey, A. , Christensen, C. B., Dafalla, M., el Kadaro, A. Y., el Hassan and Theander, T. G.; Clip. Exp. Immunology 100, 239-245, 1995), that the production of y-interferon determines the degree of severity of the Leishmania infection.
From the content of the paper of Badaro & Johnson (Badaro, R. and Johnson, W. D., J. Infect. Dis. 167, S13-515, 1994) one can see that clinical attempts, to make adequate treatment of human Leishmania infection available by the administration of y-interferon, did not show the expected success. The functional immune defense could not be restored by administration of this cytokine.
Among others, infections by intracellular parasitary pathogens, which can ..
trigger TH1/TH2 diseases according to the invention, include especially the following: trypanosomoses (Trypanosome cruzi, Trypanosome equiperdium), toxoplasmoses (Toxoplasma gondii~, mycosis (Mycosis fungoides), Candida infections (Candida), tuberculosis (Mycobacterium tuberculosis), leprosy (Mycobacterium leprae), bordetella (Bordetella pertussis), listerioses (Listeria), chlamydioses (Chlamydia) and BCG (Calmette-Guerin bacillus).
major, L. braziliensis, L. mexicana). L. attacks exclusively the endolysosomal compartments of macrophages. The immune response is based only on CD4+ cells.
Heinzel et al. (Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R.
L. and Locksley, R. M.; J. Exp. Medecine 169, 59-72, 1989) and Kemp et al. (Kemp, M., Theander, T. G. and Kharazmi, A.; Immunology today 17, 13-16, 1996) have infected two different resistant bred strains (C57BL/6 or C3H/Hel~ with L. major using the experimental mouse model for leishmanioses that reflects the human-immunological relationships. It is known from the document cited above, that especially the TH1 subclass of the CD4+ cells is responsible for the resistance of both bred strains.
Moreover, it is known from the papers of Heinzel, F. P., Sadick, M. D., Holaday, B. J. , Coffman, R. L. , and Locksley, R. M. , Journal of Experimental Medicine 169, 59-72, 1989 and Sadick, M. D., Locksley, R.
M., Tubbs, C. and Ruff, H. V.; J. Immunol. 136, 655-661, 1986; that the genetically nonresistant mouse strains such as Balb/c, react immunologically to the Leishmania infection with activation of the TH2 cells, but these cannot combat the Leishmania infection as signallers for antibody production.
Kemp, M. , Theander, T. G. and Kharazmi, A. (Immunology today 17, 13-2 5 16, 1996) showed that in human infection with L. - corresponding to the mouse model - an activation pattern of TH1 or TH2 cells exists which correspond to resistance or nonresistance.
._ ____.__ .. _._._ _ . ._ . .. . _. .._.._ _ . .. _.__. .. . . __ _ _ . ._ .
_ .. _ o .___ .. __.. _ __ ._ .. ___ . _ From the publication of Mosmann & Coffman (Mosmann, T. R. and Coffman, R. L., Annu. Rev. Immunol. 7, 145, 1989) it is known that a characteristic pattern of cytokines accompanies the activation of TH1- or TH2 cells. Thus, TH1 cells produce especially y-interferon (IFN-y), while 5 TH2 cells produce interleukin-4 (ZL-4).
It was shown both for the mouse model (Kemp, M. , Theander, T. G. and Kharazmi, A.; Immunology today 17, 13-16, 1996) as well as by clinical experiments (Gaafar, A. , Kharazmi, A. , Ismail, A. , Kemp, M. , Hey, A. , Christensen, C. B., Dafalla, M., el Kadaro, A. Y., el Hassan and Theander, T. G.; Clip. Exp. Immunology 100, 239-245, 1995), that the production of y-interferon determines the degree of severity of the Leishmania infection.
From the content of the paper of Badaro & Johnson (Badaro, R. and Johnson, W. D., J. Infect. Dis. 167, S13-515, 1994) one can see that clinical attempts, to make adequate treatment of human Leishmania infection available by the administration of y-interferon, did not show the expected success. The functional immune defense could not be restored by administration of this cytokine.
Among others, infections by intracellular parasitary pathogens, which can ..
trigger TH1/TH2 diseases according to the invention, include especially the following: trypanosomoses (Trypanosome cruzi, Trypanosome equiperdium), toxoplasmoses (Toxoplasma gondii~, mycosis (Mycosis fungoides), Candida infections (Candida), tuberculosis (Mycobacterium tuberculosis), leprosy (Mycobacterium leprae), bordetella (Bordetella pertussis), listerioses (Listeria), chlamydioses (Chlamydia) and BCG (Calmette-Guerin bacillus).
In the documents of Clerici and Shearer (Clerici, M. and Shearer, G. M.;
Immunology Today 14, 107-111, 1993) and Mosmann (Mosmann, T. R.;
Science 265, 193-194, 1994) it is described that immunologically problematic situations arise when, as a result of HIV infection, CD4+/TH2 cells dominate the immune response. Only TH1 cells permit an effective elimination of the infected cells of the immune system or of intracellularly occurring viruses. Thus, the immune weakness that occurs during AIDS
disease is a TH1/TH2 disease in the sense of the present invention.
The task of the present invention is to provide an adequate drug by using suitable materials or by the introduction of new material compositions, which modulate the immune response in TH1/TH2 diseases in such a way that intracellular pathogens are attacked by an effective immune response carried by the inflammatory TH1 cells.
Within the framework of the present invention, material compositions and the use of these compositions or other substances for the treatment of TH1/TH2 diseases are disclosed.
2 o Therefore, the object of the present invention is the use of Fast as an active pharmacological component for the treatment of ThI1/TFI2 diseases and the corresponding use of Fast for the production of a drug for the treatment of leishmanioses, AIDS, listerioses or.infections with other intracellular viral, bacterial or protozoological pathogens.
In TH1/TH2 diseases, there is a reduced TH1 response. For the immunological defense, especially in the case of infections with intracellular pathogens, an effective inflammatory TH1 cell response is decisive.
According to the invention, by the administration of Fast, the immune response of the TH1 cells is compensated, which, in the case of diseases such as leishmaniosis, AmS, listeriosis, trypanosomiasis, bortedella, leprosy, etc., can combat effectively the intracellularly residing pathogens of viral, bacterial or protozoological origin. The addition of Fast thus compensates a lacking or insu~cient TH1 immune response. Thus, the use of Fast is disclosed for use as a drug in TH1/TH2 diseases.
The gene product of the human Fast gene sequence is used as therapeutic agent for the treatment of TH1/TH2 diseases. Physiologically active gene products of Fast gene segments with potent apoptosis effect also come into consideration, for example, gene products shortened at the N- or C-terminal, or gene products, in which one or several intracistronic gene segments are lacking. v The use of Fast for the treatment of TH1/TH2 diseases can be applied in veterinary medicine for mammals, especially for useful animals, above all for pigs, cattle and sheep, but also for the domestic animals, such as dogs and cats, and in human pathology, to support the TH1 immune response to intracellular pathogens. Among useful animals, especially those mammals 2 0 are to be understood which serve humans in transport tasks or in the agricultural sector for producing food.
Especially preferred is the use of Fast for the treatment of human leishmanioses, including both cutaneous as well as visceral and also mucosal 2 5 leishmanioses, which are caused by L. donovani, L. infaruum, L. chagasi, L.
tropica, L. major, L. braziliensis, L. mexicana. Correspondingly, in the case of useful animals, the intracellular parasitary Leishmania species can be combatted by dosage of Fast.
.._..._ _. _._._ ___.. . _ . . _.._ . _._._.. .. ..... CA 02269034 1999-04-16 Fast induces apoptosis of the infected cells. An embodiment represents the use of Fast in the pharmacological form in vivo. In another embodiment, in vitro, the use of Fast can be, used during external blood purification.
Infected blood cells, that is, differentiated cells of the hematopoietic system, especially macrophages, are killed ex vivo by the administration of Fast.
The blood treated with Fast is then returned to the patient. Thus, in this case, Fast is applied externally, in order to avoid any undesirable side effects of the administration of Fast.
In a preferred embodiment, Fast is administered topically to the patient.
Topical application means nonsystemic application. The substance according to the invention is then applied onto the epidermis or dropped into the eye, nose or ears, so that essentially it does not enter into the blood stream.
Formulations of liquid, semiliquid or semisolid type are suitable for topical application. They are applied onto the cutaneous or mucosal lesions in a form that is able to be resorted. For example, cream-like formulations, salves, pastes, drops or lotions are available. The topical application of Fast can also be done in the solid form by providing powders.
Salves, pastes or cream formulations contain the active substance as an aqueous or nonaqueous solution or suspension based on a fat-containing or nonfat carrier substance.
2 5 In another preferred embodiment, the Fast is applied systemically, using oral, intravenous, intraperitoneal and intramuscular forms of administration.
The formulation for parenteral application is especially preferred.
Immunology Today 14, 107-111, 1993) and Mosmann (Mosmann, T. R.;
Science 265, 193-194, 1994) it is described that immunologically problematic situations arise when, as a result of HIV infection, CD4+/TH2 cells dominate the immune response. Only TH1 cells permit an effective elimination of the infected cells of the immune system or of intracellularly occurring viruses. Thus, the immune weakness that occurs during AIDS
disease is a TH1/TH2 disease in the sense of the present invention.
The task of the present invention is to provide an adequate drug by using suitable materials or by the introduction of new material compositions, which modulate the immune response in TH1/TH2 diseases in such a way that intracellular pathogens are attacked by an effective immune response carried by the inflammatory TH1 cells.
Within the framework of the present invention, material compositions and the use of these compositions or other substances for the treatment of TH1/TH2 diseases are disclosed.
2 o Therefore, the object of the present invention is the use of Fast as an active pharmacological component for the treatment of ThI1/TFI2 diseases and the corresponding use of Fast for the production of a drug for the treatment of leishmanioses, AIDS, listerioses or.infections with other intracellular viral, bacterial or protozoological pathogens.
In TH1/TH2 diseases, there is a reduced TH1 response. For the immunological defense, especially in the case of infections with intracellular pathogens, an effective inflammatory TH1 cell response is decisive.
According to the invention, by the administration of Fast, the immune response of the TH1 cells is compensated, which, in the case of diseases such as leishmaniosis, AmS, listeriosis, trypanosomiasis, bortedella, leprosy, etc., can combat effectively the intracellularly residing pathogens of viral, bacterial or protozoological origin. The addition of Fast thus compensates a lacking or insu~cient TH1 immune response. Thus, the use of Fast is disclosed for use as a drug in TH1/TH2 diseases.
The gene product of the human Fast gene sequence is used as therapeutic agent for the treatment of TH1/TH2 diseases. Physiologically active gene products of Fast gene segments with potent apoptosis effect also come into consideration, for example, gene products shortened at the N- or C-terminal, or gene products, in which one or several intracistronic gene segments are lacking. v The use of Fast for the treatment of TH1/TH2 diseases can be applied in veterinary medicine for mammals, especially for useful animals, above all for pigs, cattle and sheep, but also for the domestic animals, such as dogs and cats, and in human pathology, to support the TH1 immune response to intracellular pathogens. Among useful animals, especially those mammals 2 0 are to be understood which serve humans in transport tasks or in the agricultural sector for producing food.
Especially preferred is the use of Fast for the treatment of human leishmanioses, including both cutaneous as well as visceral and also mucosal 2 5 leishmanioses, which are caused by L. donovani, L. infaruum, L. chagasi, L.
tropica, L. major, L. braziliensis, L. mexicana. Correspondingly, in the case of useful animals, the intracellular parasitary Leishmania species can be combatted by dosage of Fast.
.._..._ _. _._._ ___.. . _ . . _.._ . _._._.. .. ..... CA 02269034 1999-04-16 Fast induces apoptosis of the infected cells. An embodiment represents the use of Fast in the pharmacological form in vivo. In another embodiment, in vitro, the use of Fast can be, used during external blood purification.
Infected blood cells, that is, differentiated cells of the hematopoietic system, especially macrophages, are killed ex vivo by the administration of Fast.
The blood treated with Fast is then returned to the patient. Thus, in this case, Fast is applied externally, in order to avoid any undesirable side effects of the administration of Fast.
In a preferred embodiment, Fast is administered topically to the patient.
Topical application means nonsystemic application. The substance according to the invention is then applied onto the epidermis or dropped into the eye, nose or ears, so that essentially it does not enter into the blood stream.
Formulations of liquid, semiliquid or semisolid type are suitable for topical application. They are applied onto the cutaneous or mucosal lesions in a form that is able to be resorted. For example, cream-like formulations, salves, pastes, drops or lotions are available. The topical application of Fast can also be done in the solid form by providing powders.
Salves, pastes or cream formulations contain the active substance as an aqueous or nonaqueous solution or suspension based on a fat-containing or nonfat carrier substance.
2 5 In another preferred embodiment, the Fast is applied systemically, using oral, intravenous, intraperitoneal and intramuscular forms of administration.
The formulation for parenteral application is especially preferred.
As carrier materials for systemic application, especially those in the following cited forms of administration come into consideration (Hartke &
Mutschler, Deutsches Arzneibuch, 9th Edition, 1986, Volume 3 "Parenteralia", p. 2670-2677, Wissenschaftliche Verlagsgesellschaft Stuttgart, Govi-Verlag GmbH Frankfurt; Phalnacopoeia Helvetica, Edition Septima 1/1/1991 and the revised version of 1996, Monograph "Parenteralia", US Pharmacopeia, National Formulary 18, 1995, p. 1650-1652).
Depending on the type of application (especially depending on the systemic or topical application, application in vivo or ex vivo), on the adjuvants of the particular galenic preparation, on the infection type, on the infection stage and on the current course of infection as well as depending on the known clinical parameters, for example, on the patient's age and the specific anamnesis of the patient, Fast is administered to the patient at a dose between 1 picogram and 100 mg per kg of body weight (of the patient).
Application at a concentration between 10-$ and 10-' g/kg of body weight is preferred.
2 0 In an especially preferred embodiment, the active Fast substance is combined with other pharmacological carrier materials, which, for example, improve the phartnacokinetic properties, while at the same are also physiologically compatible.
2 5 Human Fast; /CD4+/TH1 cells or cells which express Fast only weakly can be transfected with Fast. The incorporation of Fast gene material can be done by lipofection, microinjection, with the aid of viral vectors or by electroporation. The Fast gene material can be provided with a preconnected promoter and can be transfected in this form, but also it can be inserted in a targeted manner at the position of the physiological promoter.
Clonogenes, cells transfected by the standard method, which express Fast stably, are used therapeutically for TH1/TH2 diseases in order to enhance the TH1 immune response.
For this purpose, T-lymphocytes are taken from the infected patients and those TH1 cells are isolated whose T-cell receptors recognize antigens of the particular infectious pathogen. These cells are cultivated and transfected with Fast gene material. The Fast gene material can include both the 10 human Fast gene sequence as well as physiologically active Fast segments or gene segments which are potent in the apoptosis reaction, which express an Fast protein shortened at the N- or C-terminal. Stable transfected clonogenous, autologous cells are then applied again into the patient with Fast deficiency or suppressed TH1 immune response. In this special embodiment, the TH1 cells transfected with Fast serve for treating TH1/TH2 diseases. This covers the same infection spectrum that was already described above for the treatment with Fast. The transfected, autologous cells mobilize the FasL/FasR apoptosis system and kill the infected cells, especially macrophages:
According to the invention, it was found that TH1 lymphocytes can kill Leishmania-infected macrophages in vitro.
In order to check this ability of TH1 lymphocytes experimentally, 2 5 macrophages infected with Leishmania and activated were cocultivated with Leishmania-induced TH1 cells in the presence of y-interferon. The TH1 cells were taken from the lymph nodes of C57BL/6 mice, which were previously infected with Leishmania major for 5 to 8 weeks,- by removing the lymph nodes which take care of the lesions, and obtaining from them the TH1 cells, purified by the MACS method (Miltenyi Biotech GmbH, Bergisch-Gladbach). This material was restimulated in vitro by promastigotes of L. major (previously treated with UV radiation) in the presence of an irradiated (3000 rad), normal lymph node population, in which the CD4+/T cells were eliminated and which served as a source of antigen-presenting cells (APC). The TH1 cell type was confirmed by measurement of the y-interferon and interleukin-2 (IL-2) activity. After 72 h, the CD4+ "blast" cells ("blast" cells are those cells which, after stimulation, went through a clonal expansion) were isolated and washed.
They were cocultivated with bone marrow macrophages, which were previously infected with L. major in a ratio of 1:1 and in the presence of y-interferon (SO U/mL). It was found that after cocultivation for 6 hours, 60 % of the macrophages from the C57BL/6 strain were apoptotic. On the other hand, those macrophages which were treated analogously but which were taken from the syngenic FasR deficient raised mouse strain lpr showed almost no apoptotic characteristics.
In order to check the function of the FasL/FasR-controlled apoptosis signal more thoroughly, moreover, according to the invention, in vivo experiments 2 0 undertaken with the bred mouse strains C57BL/6 (resistant strain) and the syngenic mouse strains gld (Fast: ) and lpr (FasR ), all of which were mouse strains gld (FasI: ) and lpr (FasR ), all of which with Leishmania infected subcutaneously with Leishmania major promastigotes (in the stationary phase) subcutaneously at a dosage of 2 x 106 (in an end volume of 50 ~cL).
In all three of the above strains, the development of the Leishmania infection was followed once a week with the aid of the size of the lesions in the paw of the mouse and measured with a ruler, comparing the size of the infected paw with the size of the opposite, not infected paw.
Mutschler, Deutsches Arzneibuch, 9th Edition, 1986, Volume 3 "Parenteralia", p. 2670-2677, Wissenschaftliche Verlagsgesellschaft Stuttgart, Govi-Verlag GmbH Frankfurt; Phalnacopoeia Helvetica, Edition Septima 1/1/1991 and the revised version of 1996, Monograph "Parenteralia", US Pharmacopeia, National Formulary 18, 1995, p. 1650-1652).
Depending on the type of application (especially depending on the systemic or topical application, application in vivo or ex vivo), on the adjuvants of the particular galenic preparation, on the infection type, on the infection stage and on the current course of infection as well as depending on the known clinical parameters, for example, on the patient's age and the specific anamnesis of the patient, Fast is administered to the patient at a dose between 1 picogram and 100 mg per kg of body weight (of the patient).
Application at a concentration between 10-$ and 10-' g/kg of body weight is preferred.
2 0 In an especially preferred embodiment, the active Fast substance is combined with other pharmacological carrier materials, which, for example, improve the phartnacokinetic properties, while at the same are also physiologically compatible.
2 5 Human Fast; /CD4+/TH1 cells or cells which express Fast only weakly can be transfected with Fast. The incorporation of Fast gene material can be done by lipofection, microinjection, with the aid of viral vectors or by electroporation. The Fast gene material can be provided with a preconnected promoter and can be transfected in this form, but also it can be inserted in a targeted manner at the position of the physiological promoter.
Clonogenes, cells transfected by the standard method, which express Fast stably, are used therapeutically for TH1/TH2 diseases in order to enhance the TH1 immune response.
For this purpose, T-lymphocytes are taken from the infected patients and those TH1 cells are isolated whose T-cell receptors recognize antigens of the particular infectious pathogen. These cells are cultivated and transfected with Fast gene material. The Fast gene material can include both the 10 human Fast gene sequence as well as physiologically active Fast segments or gene segments which are potent in the apoptosis reaction, which express an Fast protein shortened at the N- or C-terminal. Stable transfected clonogenous, autologous cells are then applied again into the patient with Fast deficiency or suppressed TH1 immune response. In this special embodiment, the TH1 cells transfected with Fast serve for treating TH1/TH2 diseases. This covers the same infection spectrum that was already described above for the treatment with Fast. The transfected, autologous cells mobilize the FasL/FasR apoptosis system and kill the infected cells, especially macrophages:
According to the invention, it was found that TH1 lymphocytes can kill Leishmania-infected macrophages in vitro.
In order to check this ability of TH1 lymphocytes experimentally, 2 5 macrophages infected with Leishmania and activated were cocultivated with Leishmania-induced TH1 cells in the presence of y-interferon. The TH1 cells were taken from the lymph nodes of C57BL/6 mice, which were previously infected with Leishmania major for 5 to 8 weeks,- by removing the lymph nodes which take care of the lesions, and obtaining from them the TH1 cells, purified by the MACS method (Miltenyi Biotech GmbH, Bergisch-Gladbach). This material was restimulated in vitro by promastigotes of L. major (previously treated with UV radiation) in the presence of an irradiated (3000 rad), normal lymph node population, in which the CD4+/T cells were eliminated and which served as a source of antigen-presenting cells (APC). The TH1 cell type was confirmed by measurement of the y-interferon and interleukin-2 (IL-2) activity. After 72 h, the CD4+ "blast" cells ("blast" cells are those cells which, after stimulation, went through a clonal expansion) were isolated and washed.
They were cocultivated with bone marrow macrophages, which were previously infected with L. major in a ratio of 1:1 and in the presence of y-interferon (SO U/mL). It was found that after cocultivation for 6 hours, 60 % of the macrophages from the C57BL/6 strain were apoptotic. On the other hand, those macrophages which were treated analogously but which were taken from the syngenic FasR deficient raised mouse strain lpr showed almost no apoptotic characteristics.
In order to check the function of the FasL/FasR-controlled apoptosis signal more thoroughly, moreover, according to the invention, in vivo experiments 2 0 undertaken with the bred mouse strains C57BL/6 (resistant strain) and the syngenic mouse strains gld (Fast: ) and lpr (FasR ), all of which were mouse strains gld (FasI: ) and lpr (FasR ), all of which with Leishmania infected subcutaneously with Leishmania major promastigotes (in the stationary phase) subcutaneously at a dosage of 2 x 106 (in an end volume of 50 ~cL).
In all three of the above strains, the development of the Leishmania infection was followed once a week with the aid of the size of the lesions in the paw of the mouse and measured with a ruler, comparing the size of the infected paw with the size of the opposite, not infected paw.
The present invention concerns a material composition containing Fast and one or several cytokines, especially y-interferon, especially such a material composition as a drug, especially for the in vivo treatment. The use of the corresponding material composition according to the invention for the treatment of TH1/TH2 diseases is claimed, for example, for use of the treatment of leishmanioses, AIDS, listerioses or infections with other intracellular viral, bacterial or protozoological pathogens or in a preferred form for the treatment of cutaneous, visceral or mucosal leishmanioses.
The invention is concerned with the use of autologous CD4+/FasL~/TH1 cell lines of patients which were transfected with the Fast gene sequence or with physiologically active segments of the Fast gene sequence for the treatment of TH1/TH2 diseases, for example, with the use of CD4+/FasL-/TH1 cell lines transfected with Fast for the treatment of leishmanioses, AIDS, listerioses or infections with other intracellular, viral, bacterial or protozoological pathogens, whereby especially the use of CD4+/FasI:/THl cell lines transfected with Fast is claimed for the treatment of cutaneous, visceral or mucosal leishmanioses.
2 0 The invention is explained in more detail with the aid of the following figures.
In Figure 1, it is shown that the resistant control strain CS?BL/6 showed almost no sign of lesions any longer 12 weeks after the infection event, as 2 5 expected. On the other hand, it is also clear from Figure 1 that a progressive increase of the size of lesions is observed in the two other mouse strains, Ipr and gld. This experiment underlines the importance of functional Fast and FasR for an effective inflammatory TH1 effector function. The axes show on the abscissa the number of weeks after the infection event and, on the ordinate, the size of the lesion in mm.
In Figure 2, it is shown with the aid of dilution series, that the number of Leishmania parasites is significantly increased in the lesions of lpr or gld mice in comparison to samples from the lesions of the mouse control group which has a functioning FasL/FasR signal transfer system (C57BL/6). The number of parasites per mg of tissue is plotted on the abscissa. For each of the three mouse strains (with the exception of lpr mice), the number of parasites was determined after 30 and 90 days. For the lpr mice, the number of parasites was not determined after 90 days (ND).
It is shown in Figure 3 that, after an in vitro restimulation of the TH1 cells, a comparable production of y-interferon can be detected in all three mouse strains (control group, lpr and glc~.
On the other hand, IL-4 (not shown in the Figures), which is characteristic for TH2 cells, is almost undetectable. Thus it is proven experimentally that both mutant strains have wild-type properties with regard to cell proliferation 2 0 and cytokine. production. Moreover, this experiment shows that, in the mutant strains, there is adequate cytokine production for the initiation of a TH1 immune response.
Figure 4 shows that potential influences of the immunologically active CD8+-T-cells with their characteristic cytotoxic effector function can be excluded by perforin secretion in case of Leishmania infection. A perforin-deficient mouse strain (knock-out, ko) shows the same kinetic profile in the elimination of the infectious pathogen as the wild-type strains. The axes show the number of weeks after the infection event on the abscissa and the size of lesion in mm on the ordinate.
Figure S shows the size of the lesions as a function of time after the original Leishmania infection with L. major in gld mice, which are known to be Fast-deficient, (1) after the administration of Fast in the form of a supernatant of Fast-expressing cell cultures, (2) without administration of Fast and (3) in mice of the control strain C57BL/6, which did not receive any Fast injections either. The number of weeks after the infection is 1 o shown on the abscissa and the size of the lesion in mm on the ordinate.
For this purpose, gld mice were infected with L. major (5 weeks of duration of infection) and then in case (1), in the subsequent three weeks were injected with 50 ~.L of a 5-fold concentrated solution of the supernatant of FasL-produced neuro-2a-cell cultures every four days. In case (1), the FasL-containing solution was injected into the lesions.
Those gld mice which did not receive any Fast injection show an average lesion size of 1.3 mm nine weeks after the infection. On the other hand, the wild-type mice with functional Fast and FasR production, even without the 2 0 addition of Fast, show only an average lesion size of 0.3 mm after the same time period. Mice of the gld strain, which received injections with Fast samples show a clearly reduced lesion size in comparison to the untreated gld mouse, with an average size of 0.75 mm.
2 5 In Figure 6, the number of parasites per mg tissue is shown on the abscissa for the mouse strain gld, treated with Fast or with a control sample, and for the control strain C57BL/6. The result of this experiment is comparable with the results from Figure 5. Seven days after the last injection of Fast samples or control samples from supernatants of pseudotransfected neuro-2a-cells in the gld mouse, more than 40 parasites were detected in 1 mg tissue for the mice treated with Fast' control samples. Only approximately eight parasites/mg of tissue were detected in the gld mice treated with Fast. The control group of the resistant C57BL/6 mice had almost no parasites in their 5 lesions 63 days after the infection event.
The results of these experiments, shown in Figures 5 and 6, can be summarized by saying that only a cooperation of functional FasR with functional Fast genes or their functional expression products ensures 10 effective immunological defense against Leishmania infection based on the TH1 reaction.
It is known from the literature (Swihart, K. , Fruth, U. , Messmer, N. , Hug, K. , Behin, R. , Huang, S. , Del Giudice, G. , Aguet, M. and Louis, J. A. ; J.
The invention is concerned with the use of autologous CD4+/FasL~/TH1 cell lines of patients which were transfected with the Fast gene sequence or with physiologically active segments of the Fast gene sequence for the treatment of TH1/TH2 diseases, for example, with the use of CD4+/FasL-/TH1 cell lines transfected with Fast for the treatment of leishmanioses, AIDS, listerioses or infections with other intracellular, viral, bacterial or protozoological pathogens, whereby especially the use of CD4+/FasI:/THl cell lines transfected with Fast is claimed for the treatment of cutaneous, visceral or mucosal leishmanioses.
2 0 The invention is explained in more detail with the aid of the following figures.
In Figure 1, it is shown that the resistant control strain CS?BL/6 showed almost no sign of lesions any longer 12 weeks after the infection event, as 2 5 expected. On the other hand, it is also clear from Figure 1 that a progressive increase of the size of lesions is observed in the two other mouse strains, Ipr and gld. This experiment underlines the importance of functional Fast and FasR for an effective inflammatory TH1 effector function. The axes show on the abscissa the number of weeks after the infection event and, on the ordinate, the size of the lesion in mm.
In Figure 2, it is shown with the aid of dilution series, that the number of Leishmania parasites is significantly increased in the lesions of lpr or gld mice in comparison to samples from the lesions of the mouse control group which has a functioning FasL/FasR signal transfer system (C57BL/6). The number of parasites per mg of tissue is plotted on the abscissa. For each of the three mouse strains (with the exception of lpr mice), the number of parasites was determined after 30 and 90 days. For the lpr mice, the number of parasites was not determined after 90 days (ND).
It is shown in Figure 3 that, after an in vitro restimulation of the TH1 cells, a comparable production of y-interferon can be detected in all three mouse strains (control group, lpr and glc~.
On the other hand, IL-4 (not shown in the Figures), which is characteristic for TH2 cells, is almost undetectable. Thus it is proven experimentally that both mutant strains have wild-type properties with regard to cell proliferation 2 0 and cytokine. production. Moreover, this experiment shows that, in the mutant strains, there is adequate cytokine production for the initiation of a TH1 immune response.
Figure 4 shows that potential influences of the immunologically active CD8+-T-cells with their characteristic cytotoxic effector function can be excluded by perforin secretion in case of Leishmania infection. A perforin-deficient mouse strain (knock-out, ko) shows the same kinetic profile in the elimination of the infectious pathogen as the wild-type strains. The axes show the number of weeks after the infection event on the abscissa and the size of lesion in mm on the ordinate.
Figure S shows the size of the lesions as a function of time after the original Leishmania infection with L. major in gld mice, which are known to be Fast-deficient, (1) after the administration of Fast in the form of a supernatant of Fast-expressing cell cultures, (2) without administration of Fast and (3) in mice of the control strain C57BL/6, which did not receive any Fast injections either. The number of weeks after the infection is 1 o shown on the abscissa and the size of the lesion in mm on the ordinate.
For this purpose, gld mice were infected with L. major (5 weeks of duration of infection) and then in case (1), in the subsequent three weeks were injected with 50 ~.L of a 5-fold concentrated solution of the supernatant of FasL-produced neuro-2a-cell cultures every four days. In case (1), the FasL-containing solution was injected into the lesions.
Those gld mice which did not receive any Fast injection show an average lesion size of 1.3 mm nine weeks after the infection. On the other hand, the wild-type mice with functional Fast and FasR production, even without the 2 0 addition of Fast, show only an average lesion size of 0.3 mm after the same time period. Mice of the gld strain, which received injections with Fast samples show a clearly reduced lesion size in comparison to the untreated gld mouse, with an average size of 0.75 mm.
2 5 In Figure 6, the number of parasites per mg tissue is shown on the abscissa for the mouse strain gld, treated with Fast or with a control sample, and for the control strain C57BL/6. The result of this experiment is comparable with the results from Figure 5. Seven days after the last injection of Fast samples or control samples from supernatants of pseudotransfected neuro-2a-cells in the gld mouse, more than 40 parasites were detected in 1 mg tissue for the mice treated with Fast' control samples. Only approximately eight parasites/mg of tissue were detected in the gld mice treated with Fast. The control group of the resistant C57BL/6 mice had almost no parasites in their 5 lesions 63 days after the infection event.
The results of these experiments, shown in Figures 5 and 6, can be summarized by saying that only a cooperation of functional FasR with functional Fast genes or their functional expression products ensures 10 effective immunological defense against Leishmania infection based on the TH1 reaction.
It is known from the literature (Swihart, K. , Fruth, U. , Messmer, N. , Hug, K. , Behin, R. , Huang, S. , Del Giudice, G. , Aguet, M. and Louis, J. A. ; J.
15 Fxp. Med. 181, 1995), that y-interferon (IFN-y) is of decisive importance for the effectiveness of the immune response in leishmanioses. Mouse strains with genetically resistant disposition to leishmanioses show an insignificant course of the infection as long as they do not have a functional IFN-'y receptor.
In various documents (Green, S. J., Nacy, C, A. and Meltzer, M. S., J.
Leukoc. Biol. 50, 93-103, 1991; Mauel, J., Betz-Corradin, S. and Buchmuller-Rouiller, Y.; Res. Immunol. 7, 145, 1989; Wei, X.-Q., Charles, I. G., Smith, A., Ure, J., Feng, G.-J., Huang, F.-P., Damo, X., Muller, W., Moncada, S. and Liew, F. Y.; Nature 375, 408-411, 1995) the effect of IFN-y is attributed to the induction of NO synthase, which increases NO synthesis.
In various documents (Green, S. J., Nacy, C, A. and Meltzer, M. S., J.
Leukoc. Biol. 50, 93-103, 1991; Mauel, J., Betz-Corradin, S. and Buchmuller-Rouiller, Y.; Res. Immunol. 7, 145, 1989; Wei, X.-Q., Charles, I. G., Smith, A., Ure, J., Feng, G.-J., Huang, F.-P., Damo, X., Muller, W., Moncada, S. and Liew, F. Y.; Nature 375, 408-411, 1995) the effect of IFN-y is attributed to the induction of NO synthase, which increases NO synthesis.
According to the invention, it was found that IFN-y promotes the expression of FasR on macrophages infected with Leishmania.
It is shown in Figure 7 that the expression of FasR both in the wild-type as well as in gld mice is increased after the administration of IFN-y. On the other hand, this effect is not detectable in the FasR deficient lpr mice. Bone marrow macrophages were taken from six-week old mice of the strain Bone marrow macrophages were taken from six-week old mice of the strain C57BL/6, and were cultured according to the data of Feng et al. (Feng, Z.
Y. , Louis, J. , Kindler, V. , Pedrazzini, T. , Eliason, J. F. , Behin, R. and Vasalli, P.; Eur. J. Immunol. 18, 1245-1251, 1988). After that, the macrophages were infected with promastigotes of Leishmania in a ratio of 5:1, washed after 12 hours and were cultured again in the presence of IFN-y (50 U/mL) for another 48 h in the culture. After marking with monoclonal anti-Macl antibodies M1/70, 98 % of the macrophages gave a positive signal. Moreover, the macrophages were marked with a control antibody, a biotinylated anti-Fas antibody (J02, Pharmingen, USA) or with a biotinylated monoclonal anti-MHC-II antibody (monoclonal Ak BP10~ and then fluorescing Streptavidin (Caltag, USA) was added. The analysis was 2 o carried out on an FACScanr flow-through cytometer (Becton Dickinson, Mountain View, CA, USA).
Furthermore, according to the invention, it was shown that the activation of the expression of FasR on the macrophages produced by IFN-y led to a 2 5 higher sensitivity of the cells to an Fast-controlled apoptosis. The three mouse strains named above were used for the experimental detection of IFN-y-activated macrophages infected with Leishmania. As was described in the previous paragraph, these cells were raised for 48 h in the culture and then treated with the supernatant of recombinant Fast-producing neuro-2a cells or pseudotransfected neuro-2a cells (Rensing-Ehl, A. , Frei, K. , Flury, F. , Matiba, B., Mariani, S. M., Weller, M., Aebischer, P., Krammer, P. H.
and Fontana, A.; Eur. J. Immunol. 25, 2253-2258, 1995). Apoptotic cells were determined with the aid of subdiploid DNA according to the method of Renno et al. (Renno, T., Hahne, M., Tschopp, J. and MacDonald, H. R., J.
Exp. Med. 183, 431-437, 1996).
Thus, through the FasL/FasR system, TH1 cells can introduce the apoptosis of macrophages infected with Leishmania or other intracellular pathogens when and as long as the macrophages were activated first with IFN-'y.
According to the present invention, the IFN-y production for the stimulation of NO synthesis is not sufficient to explain the experiments on the immune reactions of mouse strain C57BL/6, gld and lpr toward the Leishmania pathogens.
It is shown in Figure 8 that the macrophages of the three strains have approximately comparable rate of synthesis of NO after the addition of IFN-y. Thus, according to the invention, in addition to the known mechanism of NO production, the activation of the FasR expression also occurs as a result 2 0 of a corresponding stimulation by IFN-y to combat intracellular infection in antigen-presenting cells.
The present invention will be explained in more detail with practical examples.
First of all, the experimental boundary conditions on which all the following practical examples were based will be explained.
It is shown in Figure 7 that the expression of FasR both in the wild-type as well as in gld mice is increased after the administration of IFN-y. On the other hand, this effect is not detectable in the FasR deficient lpr mice. Bone marrow macrophages were taken from six-week old mice of the strain Bone marrow macrophages were taken from six-week old mice of the strain C57BL/6, and were cultured according to the data of Feng et al. (Feng, Z.
Y. , Louis, J. , Kindler, V. , Pedrazzini, T. , Eliason, J. F. , Behin, R. and Vasalli, P.; Eur. J. Immunol. 18, 1245-1251, 1988). After that, the macrophages were infected with promastigotes of Leishmania in a ratio of 5:1, washed after 12 hours and were cultured again in the presence of IFN-y (50 U/mL) for another 48 h in the culture. After marking with monoclonal anti-Macl antibodies M1/70, 98 % of the macrophages gave a positive signal. Moreover, the macrophages were marked with a control antibody, a biotinylated anti-Fas antibody (J02, Pharmingen, USA) or with a biotinylated monoclonal anti-MHC-II antibody (monoclonal Ak BP10~ and then fluorescing Streptavidin (Caltag, USA) was added. The analysis was 2 o carried out on an FACScanr flow-through cytometer (Becton Dickinson, Mountain View, CA, USA).
Furthermore, according to the invention, it was shown that the activation of the expression of FasR on the macrophages produced by IFN-y led to a 2 5 higher sensitivity of the cells to an Fast-controlled apoptosis. The three mouse strains named above were used for the experimental detection of IFN-y-activated macrophages infected with Leishmania. As was described in the previous paragraph, these cells were raised for 48 h in the culture and then treated with the supernatant of recombinant Fast-producing neuro-2a cells or pseudotransfected neuro-2a cells (Rensing-Ehl, A. , Frei, K. , Flury, F. , Matiba, B., Mariani, S. M., Weller, M., Aebischer, P., Krammer, P. H.
and Fontana, A.; Eur. J. Immunol. 25, 2253-2258, 1995). Apoptotic cells were determined with the aid of subdiploid DNA according to the method of Renno et al. (Renno, T., Hahne, M., Tschopp, J. and MacDonald, H. R., J.
Exp. Med. 183, 431-437, 1996).
Thus, through the FasL/FasR system, TH1 cells can introduce the apoptosis of macrophages infected with Leishmania or other intracellular pathogens when and as long as the macrophages were activated first with IFN-'y.
According to the present invention, the IFN-y production for the stimulation of NO synthesis is not sufficient to explain the experiments on the immune reactions of mouse strain C57BL/6, gld and lpr toward the Leishmania pathogens.
It is shown in Figure 8 that the macrophages of the three strains have approximately comparable rate of synthesis of NO after the addition of IFN-y. Thus, according to the invention, in addition to the known mechanism of NO production, the activation of the FasR expression also occurs as a result 2 0 of a corresponding stimulation by IFN-y to combat intracellular infection in antigen-presenting cells.
The present invention will be explained in more detail with practical examples.
First of all, the experimental boundary conditions on which all the following practical examples were based will be explained.
The mouse strains C57BL/6 and C3H/HeN were purchased from IFFA-CREDO (Saint Germain-sur-1'Abresle, France). The two deficient mouse strains gld (Fast-) and lpr (FasR-) are derived from the strains C57BL/6 or C3H/HeN and were bred in Jacksons Laboratorium (Bar Harbor, Maine, USA). All mice were six to eight weeks old at the time of the experiments.
The Leishmania parasites of the strain L. major LV 39 (MRHO/SU/59/P-strain) were stored in vtvo and raised in vitro according to the method of Louis, J. A., Moedder, E., Behin, R., Engers, H. D. (Eur. J. Immunol., 9, l0 841-847, 1979).
The infection of the mice with the parasites was done subcutaneously in one paw with 2 x 106 promastigotes in the stationary phase with an end volume of 50 ~.L.
The recombinant Fast was expressed in neuro-2a cells according to the method of Rensing-Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S.
M., Weller, M., Aebischer, P., Krammer, P. H. and Fontana, A. (Eur. J.
Immunol. 25, 2253-2258, 1995).
The apoptotic cells were determined according to the method of Renno, T., Hahne, M., Tschopp, J. and MacDonald, H. R. (J. Exp. Med. 183, 431-437, 1996) based on the content of subdiploid DNA.
2 5 The bone marrow macrophages originate from bone marrow precursor cells (after in vitro differentiation) which was carned out according to the method of Feng et al. (Feng, Z. Y. , Louis, J. , Kindler, V. , Pedrazzini, T. , Eliason, J. F., Behin, R. and Vasalli, P.; Eur. J. Immunol. 18, 1245-1251, 1988).
The Leishmania parasites of the strain L. major LV 39 (MRHO/SU/59/P-strain) were stored in vtvo and raised in vitro according to the method of Louis, J. A., Moedder, E., Behin, R., Engers, H. D. (Eur. J. Immunol., 9, l0 841-847, 1979).
The infection of the mice with the parasites was done subcutaneously in one paw with 2 x 106 promastigotes in the stationary phase with an end volume of 50 ~.L.
The recombinant Fast was expressed in neuro-2a cells according to the method of Rensing-Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S.
M., Weller, M., Aebischer, P., Krammer, P. H. and Fontana, A. (Eur. J.
Immunol. 25, 2253-2258, 1995).
The apoptotic cells were determined according to the method of Renno, T., Hahne, M., Tschopp, J. and MacDonald, H. R. (J. Exp. Med. 183, 431-437, 1996) based on the content of subdiploid DNA.
2 5 The bone marrow macrophages originate from bone marrow precursor cells (after in vitro differentiation) which was carned out according to the method of Feng et al. (Feng, Z. Y. , Louis, J. , Kindler, V. , Pedrazzini, T. , Eliason, J. F., Behin, R. and Vasalli, P.; Eur. J. Immunol. 18, 1245-1251, 1988).
Cultivation of lymphocytes: the cells were taken from those lymph nodes which were in connection with L. major-produced lesions (3 x 106/mL) and were stimulated in vitro with UV-irradiated L. major promastigotes (1 x 106/mL) for 72 h or with ConA (2.5 mg/mL) for 48 h on the bottom of microtiter plates (Falcon, Switzerland). As external conditions, 37°C, an air environment enriched to 7 % COz and an end volume of 200 ~.L were chosen. The cells were cultivated in DMEM (Dulbeccos Modified Eagles Medium) with 5 % heat-inactivated FCS (Fetal Calf Serum), with L-glutamine (216 mg/mL), 5 x 10-5 M (i-ME, 10 mM Hepes, 100 UImL of penicillin and 100 mg/mL of Streptomycin. The supernatants of the corresponding cultures were combined and stored at -20°C and then they were used for the cytokine determination. In some experiments, the CD4+-T cells were removed fiom the cell suspensions by adding, after the incubation, monoclonal Ig-M antibodies against CD4 marker (RL 172.4) and Low-Tox rabbit complement (Cedarlane, Homy, Ontario, (RL 172.4) and Low-Tox rabbit complement (Cedarlane, Horny, Ontario, Canada) according to the method of Swihart, K. , Fruth, U. , Messmer, N. , Hug, K. , Behin, R. , Huang, S. , Del Giudice, G. , Aguet, M. and Louis, J. A. (J. Exp. Med.
181, 1995). In some experiments, the strength of the proliferation was also 2 0 checked by the measurement of the incorporation of 3H-methylthymidine (3htdr, Amersham, GB).
a) 1. Experimental procedure:
2 5 An in vitro test system was used for the detection of the apoptotic action of CD4+/TH1 cells on bone marrow macrophages infected with L. major.
T'he CD4+/TH1 cells were taken from mice of the bred strain C57BL/6 (IFFA-CREDO, Saint Germain-sur-1'Abresle, France), which were infected with L. major 5 to 8 weeks previously.
5 The lymph nodes in the area of the Leishmania lesions were removed and were purified by the MACS method using the procedure given by the manufacturer (Miltenyi Biotech GmbH, Bergisch-Gladbach, Germany). The purified CD4+ cells (2 x 105 per well) were stimulated in vitro by promastigotes of L. major (previously treated with UV irradiation) in the 1 o presence of irradiated (3000 rad) lymph node cell populations without CD4+
cells, so that they can be used as material for antigen-presenting cells (APC).
After 72 h, the CD4+ "blast" cells (see above) were isolated and washed.
They were cocultivated with bone marrow macrophages which were previously infected with L. major using the method described above and 15 were activated with y-interferon, in the ratio of 1:1 (in an end volume of mL in Petri dishes). After 6 h of cocultivation, the bone marrow macrophages were harvested with a plastic scraper, washed and the amount of apoptotic cells was determined by FACS analysis. For this purpose, the macrophage population was marked with monoclonal anti-MAC 1 antibodies 2 o M1/70. After marking, 98 % of the macrophages showed a positive signal.
In addition, the macrophages were marked with a control antibody, a biotinylated anti-Fas antibody (J02, Pharmingen, USA) or a biotinylated monoclonal anti-MHC-II antibody (BP107) and then fluorescent Streptavidin (Caltag, USA) was added. The analysis was carried out on an FACScanr 2 5 flow-through cytometer (Becton Dickinson, Mountain View, CA, USA).
2. Results It was found that after 6 h of cocultivation, more than 60 % of the macrophages from the C57BL/6 strain were apoptotic. On the other hand, those macrophages which were treated analogously but were taken from the syngenic FasR-deficient mouse strain lpr, showed almost no apoptotic characteristics (approximately 2 % of the cells).
b) 1. Experimental procedure The proof, that a TH1/TH2 disease can be treated effectively with Fast, was provided for various mouse strains infected with L. major. For this purpose, gld mice, which were infected 5 weeks previously with L. major, were treated for three weeks every 4 days with a fivefold concentrated supernatant of the Fast-expressing neuro-2a cells. For this purpose, 50 ~L was injected into the Leishmania lesions. The size in the lesion was determined during the entire experiment over nine weeks. The size of the lesions was determined with the aid of a ruler which permitted measurement of the thickness of the infected paw in comparison to the thickness of the opposite, noninfected paw. Control mice, which were also infected, were treated with the supernatant of neuro-2a pseudotransfectants, which do not express any Fast (Rensing-Ehl, A. , Frei, K. , Flury, R. , Matiba, B. , Mariani, S . M. , Weller, M., Aebischer, P., Kxxmmer, P. H. and Fontana, A.; Eur. J.
2 0 Immunol. 25, 2253-2258, 1995). Seven days after the end of the treatment (or nine weeks after the infection), the size of the lesions and the number of parasites in the lesions were determined in gld mice treated in this way. The number of parasites in the lesions on the infected paws was determined with a dilution test at certain intervals according to the method of Titus, R. G., Marchand, M., Boon, T. and Louis, J. A. (Parasite Immunology 7, 545-555, 1985).
2. Results The result of the treatment of Fast-deficient gld mice with Fast is shown in Figures 5 and 6. Figure 5 shows the size of the lesion as a function of time (in weeks, after the infection). The three curves symbolize the following:
1. (i) gld mice, which were treated with the Fast of Fast-expressing cells for five weeks after the infection; 2. (D) gld mice, which were treated with the supernatant of Fast pseudotransfectants, and 3. (O) control mice of strain C57BL/6.
Five weeks after the infection and before the treatment with the various supernatants, the gld mice showed a lesion size of approximately 0.9 mm.
During the further observation period, the lesion size of the gld mice, into which no functional Fast was injected, increased (to approximately 1.2 mm nine weeks after the infection), while the size of the lesion was reduced in the mice which were treated with functional Fast. Nine weeks after the infection, these mice show only an average lesion size of 0.6 mm.
This experiment documents that the treatment of Fast-deficient gld mice with Fast has a significant therapeutic effect on the course of the infection.
2 0 Figure 6 shows the number of parasites per mg of tissue, determined in a dilution test, in the lesions of C57BL/6 mice, of the Fast treated gld mice and of gld mice treated with the supernatant of pseudotransfectants per mg of tissue. The determination of the number of parasites was done nine weeks after the infection and seven days after the end of the treatment.
The number of parasites is clearly reduced by the injection of Fast (less than 10 parasites per mg of tissue). On the other hand, the mice which were not treated with Fast show more than 40 parasites per mg of tissue. Thus, this experimental arrangement also demonstrates clearly the therapeutic effect of Fast in the treatment of TH1/TH2 diseases, here on the example of Leishmania infection.
c) 1. Experimental procedure In order to describe the dependence of the mechanism of apoptosis of intracellularly infected cells on the presence of y-interferon and thus to document the activity of y-interferon on the Fas mechanism, bone marrow macrophages infected with L. major were treated with IFN-'y and finally investigated for the expression of the corresponding marker proteins.
For this purpose, bone marrow cells of C57BL/6-, gld and lpr mice, where the gld and lpr mice had a C57BL/6 origin, were cultivated in 10 mL Petri dishes made of plastic (Sterilin, Hounslow, GB) in DMEM (see above) with the addition of 20 % horse serum and 30 % serum-free supernatant of L929 cells, as M-CSF donors. After seven days of cultivation, the macrophages were separated and suspended in DMEM with 10 % FCS (see above), L-glutamine (216 mg/mL), 10 mM Hepes, 100 U/mL of penicillin and 100 mg/mL of streptomycin. Then the macrophages were infected with L. major 2 0 promastigotes in a ratio of 5:1 and were taken up in an end volume of 2 mL
in Petri dishes made of plastic. Twelve hours after the infection, the bone marrow macrophages were washed and were incubated in the medium described above for 48 h with recombinant IFN-y (50 U/mL). During the last four hours of incubation, the supernatant of either Fast-producing 2 5 neuro-2a cells or neuro-2a pseudotransfectants (20 volume % ) were added to the macrophage cultures. Finally, in the macrophages, using the FACS
method described above (see under a)), the cell surface expression of MHC-II (main histocompatibility complex of class II) and FasR molecules.
2. Results Figure 7 shows the result of this experiment by plotting the number of cells against the number of Co (control)-, MHC-II- and FasR molecules for the wild type, the gld and the gld mice.
The comparable activation of the three mouse strains by IFN-y was proven by the increased expression of MFiC-II molecules. In the three strains, the integral of the number of cells and the number of expressed MHC-II
molecules is comparable. On the other hand, the number of expressed FasR
molecules as a result of the treatment with IFN-y shows characteristic differences in the individual strains. Both the wild-type strain as well as the gld strain show an increased rate of expression but not the FasR-deficient gld strain.
Thus, it becomes clear that the treatment with IFN-Y has a direct influence on the FasL/FasR controlled apoptosis signal by up-regulation of the expression rate of the FasR molecules by IFN-y.
181, 1995). In some experiments, the strength of the proliferation was also 2 0 checked by the measurement of the incorporation of 3H-methylthymidine (3htdr, Amersham, GB).
a) 1. Experimental procedure:
2 5 An in vitro test system was used for the detection of the apoptotic action of CD4+/TH1 cells on bone marrow macrophages infected with L. major.
T'he CD4+/TH1 cells were taken from mice of the bred strain C57BL/6 (IFFA-CREDO, Saint Germain-sur-1'Abresle, France), which were infected with L. major 5 to 8 weeks previously.
5 The lymph nodes in the area of the Leishmania lesions were removed and were purified by the MACS method using the procedure given by the manufacturer (Miltenyi Biotech GmbH, Bergisch-Gladbach, Germany). The purified CD4+ cells (2 x 105 per well) were stimulated in vitro by promastigotes of L. major (previously treated with UV irradiation) in the 1 o presence of irradiated (3000 rad) lymph node cell populations without CD4+
cells, so that they can be used as material for antigen-presenting cells (APC).
After 72 h, the CD4+ "blast" cells (see above) were isolated and washed.
They were cocultivated with bone marrow macrophages which were previously infected with L. major using the method described above and 15 were activated with y-interferon, in the ratio of 1:1 (in an end volume of mL in Petri dishes). After 6 h of cocultivation, the bone marrow macrophages were harvested with a plastic scraper, washed and the amount of apoptotic cells was determined by FACS analysis. For this purpose, the macrophage population was marked with monoclonal anti-MAC 1 antibodies 2 o M1/70. After marking, 98 % of the macrophages showed a positive signal.
In addition, the macrophages were marked with a control antibody, a biotinylated anti-Fas antibody (J02, Pharmingen, USA) or a biotinylated monoclonal anti-MHC-II antibody (BP107) and then fluorescent Streptavidin (Caltag, USA) was added. The analysis was carried out on an FACScanr 2 5 flow-through cytometer (Becton Dickinson, Mountain View, CA, USA).
2. Results It was found that after 6 h of cocultivation, more than 60 % of the macrophages from the C57BL/6 strain were apoptotic. On the other hand, those macrophages which were treated analogously but were taken from the syngenic FasR-deficient mouse strain lpr, showed almost no apoptotic characteristics (approximately 2 % of the cells).
b) 1. Experimental procedure The proof, that a TH1/TH2 disease can be treated effectively with Fast, was provided for various mouse strains infected with L. major. For this purpose, gld mice, which were infected 5 weeks previously with L. major, were treated for three weeks every 4 days with a fivefold concentrated supernatant of the Fast-expressing neuro-2a cells. For this purpose, 50 ~L was injected into the Leishmania lesions. The size in the lesion was determined during the entire experiment over nine weeks. The size of the lesions was determined with the aid of a ruler which permitted measurement of the thickness of the infected paw in comparison to the thickness of the opposite, noninfected paw. Control mice, which were also infected, were treated with the supernatant of neuro-2a pseudotransfectants, which do not express any Fast (Rensing-Ehl, A. , Frei, K. , Flury, R. , Matiba, B. , Mariani, S . M. , Weller, M., Aebischer, P., Kxxmmer, P. H. and Fontana, A.; Eur. J.
2 0 Immunol. 25, 2253-2258, 1995). Seven days after the end of the treatment (or nine weeks after the infection), the size of the lesions and the number of parasites in the lesions were determined in gld mice treated in this way. The number of parasites in the lesions on the infected paws was determined with a dilution test at certain intervals according to the method of Titus, R. G., Marchand, M., Boon, T. and Louis, J. A. (Parasite Immunology 7, 545-555, 1985).
2. Results The result of the treatment of Fast-deficient gld mice with Fast is shown in Figures 5 and 6. Figure 5 shows the size of the lesion as a function of time (in weeks, after the infection). The three curves symbolize the following:
1. (i) gld mice, which were treated with the Fast of Fast-expressing cells for five weeks after the infection; 2. (D) gld mice, which were treated with the supernatant of Fast pseudotransfectants, and 3. (O) control mice of strain C57BL/6.
Five weeks after the infection and before the treatment with the various supernatants, the gld mice showed a lesion size of approximately 0.9 mm.
During the further observation period, the lesion size of the gld mice, into which no functional Fast was injected, increased (to approximately 1.2 mm nine weeks after the infection), while the size of the lesion was reduced in the mice which were treated with functional Fast. Nine weeks after the infection, these mice show only an average lesion size of 0.6 mm.
This experiment documents that the treatment of Fast-deficient gld mice with Fast has a significant therapeutic effect on the course of the infection.
2 0 Figure 6 shows the number of parasites per mg of tissue, determined in a dilution test, in the lesions of C57BL/6 mice, of the Fast treated gld mice and of gld mice treated with the supernatant of pseudotransfectants per mg of tissue. The determination of the number of parasites was done nine weeks after the infection and seven days after the end of the treatment.
The number of parasites is clearly reduced by the injection of Fast (less than 10 parasites per mg of tissue). On the other hand, the mice which were not treated with Fast show more than 40 parasites per mg of tissue. Thus, this experimental arrangement also demonstrates clearly the therapeutic effect of Fast in the treatment of TH1/TH2 diseases, here on the example of Leishmania infection.
c) 1. Experimental procedure In order to describe the dependence of the mechanism of apoptosis of intracellularly infected cells on the presence of y-interferon and thus to document the activity of y-interferon on the Fas mechanism, bone marrow macrophages infected with L. major were treated with IFN-'y and finally investigated for the expression of the corresponding marker proteins.
For this purpose, bone marrow cells of C57BL/6-, gld and lpr mice, where the gld and lpr mice had a C57BL/6 origin, were cultivated in 10 mL Petri dishes made of plastic (Sterilin, Hounslow, GB) in DMEM (see above) with the addition of 20 % horse serum and 30 % serum-free supernatant of L929 cells, as M-CSF donors. After seven days of cultivation, the macrophages were separated and suspended in DMEM with 10 % FCS (see above), L-glutamine (216 mg/mL), 10 mM Hepes, 100 U/mL of penicillin and 100 mg/mL of streptomycin. Then the macrophages were infected with L. major 2 0 promastigotes in a ratio of 5:1 and were taken up in an end volume of 2 mL
in Petri dishes made of plastic. Twelve hours after the infection, the bone marrow macrophages were washed and were incubated in the medium described above for 48 h with recombinant IFN-y (50 U/mL). During the last four hours of incubation, the supernatant of either Fast-producing 2 5 neuro-2a cells or neuro-2a pseudotransfectants (20 volume % ) were added to the macrophage cultures. Finally, in the macrophages, using the FACS
method described above (see under a)), the cell surface expression of MHC-II (main histocompatibility complex of class II) and FasR molecules.
2. Results Figure 7 shows the result of this experiment by plotting the number of cells against the number of Co (control)-, MHC-II- and FasR molecules for the wild type, the gld and the gld mice.
The comparable activation of the three mouse strains by IFN-y was proven by the increased expression of MFiC-II molecules. In the three strains, the integral of the number of cells and the number of expressed MHC-II
molecules is comparable. On the other hand, the number of expressed FasR
molecules as a result of the treatment with IFN-y shows characteristic differences in the individual strains. Both the wild-type strain as well as the gld strain show an increased rate of expression but not the FasR-deficient gld strain.
Thus, it becomes clear that the treatment with IFN-Y has a direct influence on the FasL/FasR controlled apoptosis signal by up-regulation of the expression rate of the FasR molecules by IFN-y.
Claims (18)
1. Application of Fast or of an Fast segment, which is potent for apoptosis, for the production of a drug for the treatment of TH1/TH2 diseases, triggered by intracellularly residing pathogens, with the exception of viral pathogens.
2. Application of FasL ox an FasL segment which is potent for apoptosis according to Claim 1 for the preparation of a drug for the treatment of leishmanioses, listerioses or infections with other intracellular bacterial or protozoological pathogens,
3. Application of FasL according to Claim 1 or 2 for the treatment of cutaneous, visceral or mucosal leishmaniosis.
4. Application of FasL according to Claim 1, 2 ox 3 for the treatment of mammals, especially useful animals, and humans.
5. Application of FasL according to one of Claims 1 to 4 for the induction of apoptosis in vivo.
6. Application of FasL according to one of Claims 1 to 4 for the induction of apoptosis in vitro.
7. Application of FasL according to Claim 5 as a local therapeutic agent in topical application.
8. Application of FasL according to Claim 5, in systemic application, especially in the parenteral form.
9. Application of FasL according to one of the Claims mentioned above in a homogeneous form with a physiologically compatible pharmaceutical carrier material.
10. Application of Fast according to one of the above Claims, in a concentration range between 10-12 and 10-1 g/kg of body weight, preferably 10-2 and 10-3 g/kg of body weight.
11. Material composition, containing Fast and one or more cytokines, especially .gamma.-interferon.
12. Application of a material composition according to Claim 11 for the preparation of a drug, especially for in-vivo treatment.
13. Application of a material composition according to Claim 11 or 12, for the preparation of a drug for the treatment of TH1/TH2 diseases.
14. Application of a material composition according to Claim 13 for the treatment of leishmanioses, listerioses or infections with other intracellular bacterial or protozoological pathogens.
15. Application of a material composition according to Claim 14, for the treatment of cutaneous, visceral or mucosal leishmaniosis.
16. Application of autologous CD4+/FasL/THI cell lines of the patient which were transfected with the FasL gene sequence or physiologically active segments of the FasL gene sequence for the preparation of a drug for the treatment of TH1/TH2 diseases.
17. Application of CD4+/FasL-/TH1 cell lines transfected with Fast according to Claim 16 for the treatment of leishmanioses, listerioses or infections with other intracellular bacterial or protozoological pathogens.
18. Application of CD4+/FasL/TH1 cells lines transfected with FasL, according to Claim 17, for the treatment of cutaneous, visceral or mucosal leishmanioses.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19643093.3 | 1996-10-18 | ||
| DE19643093A DE19643093C2 (en) | 1996-10-18 | 1996-10-18 | Use of FasL or CD4 · + · / FasL · - · / TH1 cell lines transfected with FasL or of FasL in combination with one or more cytokines for combating TH1 / TH2 diseases |
| PCT/EP1997/005589 WO1998017305A1 (en) | 1996-10-18 | 1997-10-10 | USE OF FasL OR FasL TRANSFECTED CD4+/FasL-/TH1-CELL LINES FOR THE TREATMENT OF TH1/TH2 DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2269034A1 true CA2269034A1 (en) | 1998-04-30 |
Family
ID=7809153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002269034A Abandoned CA2269034A1 (en) | 1996-10-18 | 1997-10-10 | Use of fasl or fasl transfected cd4+/fasl-/th1-cell lines for the treatment of th1/th2 diseases |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0930890A1 (en) |
| AU (1) | AU4866497A (en) |
| CA (1) | CA2269034A1 (en) |
| DE (1) | DE19643093C2 (en) |
| WO (1) | WO1998017305A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503672A (en) * | 1993-10-14 | 1997-04-15 | イミュネックス・コーポレーション | Fas antagonist and its use |
| JPH08127594A (en) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | New protein binding to fas antigen and dna coding the same |
| JPH09508009A (en) * | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Ligands that bind Fas antigen |
| US5759536A (en) * | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
| WO1997012632A1 (en) * | 1995-10-05 | 1997-04-10 | Tkb Associates Limited Partnership | Methods for treatment of diseases associated with a deficiency of fas ligand activity |
-
1996
- 1996-10-18 DE DE19643093A patent/DE19643093C2/en not_active Expired - Fee Related
-
1997
- 1997-10-10 WO PCT/EP1997/005589 patent/WO1998017305A1/en not_active Application Discontinuation
- 1997-10-10 CA CA002269034A patent/CA2269034A1/en not_active Abandoned
- 1997-10-10 AU AU48664/97A patent/AU4866497A/en not_active Abandoned
- 1997-10-10 EP EP97911208A patent/EP0930890A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE19643093A1 (en) | 1998-04-23 |
| EP0930890A1 (en) | 1999-07-28 |
| AU4866497A (en) | 1998-05-15 |
| DE19643093C2 (en) | 1998-10-01 |
| WO1998017305A1 (en) | 1998-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khan et al. | IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. | |
| Trinchieri | Regulatory role of T cells producing both interferon γ and interleukin 10 in persistent infection | |
| Kulkarni et al. | Insights into the role of Toll-like receptors in modulation of T cell responses | |
| Prajeeth et al. | Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity | |
| Ji et al. | Analysis of T helper cell responses during infection with Leishmania amazonensis. | |
| Lian et al. | Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and Apoptin | |
| Mustafa et al. | BCG induced CD4+ cytotoxic T cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro. | |
| JPH05509093A (en) | Selected immunotherapy using interleukin-7 | |
| JP2547162B2 (en) | Methods and compositions for inhibiting allograft rejection in mammals | |
| WO1999042097A1 (en) | Small molecules that elicit a polarized th1 response and for modulation of cellular immunity | |
| JP2975117B2 (en) | Live vaccines for the treatment of tumor diseases | |
| CA2253803A1 (en) | Use of interleukin-10 to produce a population of suppressor cells | |
| Stevenson et al. | Modulation of host responses to blood-stage malaria by interleukin-12: from therapyto adjuvant activity | |
| Rager-Zisman et al. | Natural killer cells in resistance to virus-infected cells | |
| WO2009148229A2 (en) | Immunogenic peptide and composition containing the peptide for preventing or treating hpv-related diseases | |
| CA2269034A1 (en) | Use of fasl or fasl transfected cd4+/fasl-/th1-cell lines for the treatment of th1/th2 diseases | |
| WO2009148230A2 (en) | Immunogenic peptide and composition containing the peptide for preventing or treating hpv-related diseases | |
| KR20210002205A (en) | A Method for Enhancement of Cytokine from Immune cell Cultivating and Functional Cosmetics Ingredients Composition | |
| WO2017064558A1 (en) | Novel immunostimulant | |
| CA2078676A1 (en) | Use of il-4 to enhance immune response to infectious antigenic challenges | |
| Awasthi et al. | Differences in expression of cell surface co-stimulatory molecules, Toll-like receptor genes and secretion of IL-12 by bone marrow-derived dendritic cells from susceptible and resistant mouse strains in response to Coccidioides posadasii | |
| Liew | Induction and regulation of CD4+ T cell subsets | |
| Terres et al. | The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response in vivo. | |
| US6482833B2 (en) | Immunotherapeutic anti-cancer pharmaceutical compositions | |
| US6399077B1 (en) | Method of augmenting T cell-mediated immunity against Toxoplasma gondii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |